Technology Profiles
 Profile Detail
Non-invasive cardiovascular risk assesment device (10 BE 0213 3GPS)
A Brussels based SME designs, develops and produces software and electronic medical devices in order to facilitate, simplify and increase the accuracy of diagnoses. The company has developed a device for the assessment of the arterial function, allowing doctors to detect cardiovascular risks in patients.
The SME wants to develop its distribution channels worldwide and is looking for partners with the necessary technical competences for licensing, joint venture or commercial agreements.
Country: Belgium
Type: OFFER
Date: 08.03.2010
A Brussels based company designs, develops and produces software and electronic medical devices in order to facilitate, simplify and increase the accuracy of diagnoses. Currently, it focuses its research on the development of software and new medical devices to assess cardiovascular risks, in particular within the endothelial function.
Endothelial dysfunction is considered to be the first stage of atherosclerosis. Impaired endothelial function is recognized as an early and modulating process in the pathophysiology of cardiovascular disease. The assessment and characterization of endothelial function in the diagnosis of cardiovascular diseases is a topic of both clinical and research importance.
Endothelial function is actually often quantified by flow-mediated dilation (FMD), which represents the endothelium-dependent relaxation of a conduit artery - typically the brachial artery due to an increased blood flow. Brachial artery reactivity is a frequently used non-invasive ultrasonographic assessment of FMD that indicates endothelium-dependent response to shear stress. This measure is a marker for increased cardiovascular risk, and correlates with impaired endothelium-dependent relaxation in the coronary arteries.
The company offers a new device to evaluate the endothelial function by a non-invasive method, flow-mediated dilation, to assess the arterial function. It allows doctors to detect cardiovascular risks in patients.
The SME is a Brussels spin-off of two departments (Institut Superieur Industriel de Bruxelles ISIB and Institut d'Enseignement Superieur d'Ergotherapie et de Kinesitherapie ISEK) of the University College Paul-Henri Spaak and has received funding from the Institute for the encouragement of Scientific Research and Innovation of Brussels (ISRIB) of the Brussels-Capital Region.
Innovative Aspects:
The product is a non-invasive cardiovascular risk assessment device. Impaired endothelial function is an early event in atherogenesis and cardiovascular diseases and can be evaluated by the Flow-Mediated Dilation (FMD) of the brachial artery. FMD is impaired in patients with cardiovascular disease risks such as smoking, hypercholesterolemia, hypertension, atherogenesis, diabetes...
The device was developed in order to simplify the evaluation of the Flow-Mediated Dilation (FMD). This measurement is non-invasive and provides an assessments of the cardiovascular risk.
The principal innovative aspects of the device lies in the evaluation of the endothelial function and automatic data analysis. - Non invasive diagnosis of cardiovascular diseases with an endothelial function assessment (varsular reactivity)
- Non user dependent
- No need to invest in an ultrasound device
- Very easy to use
- Easy navigation and logical usability during the patient's examen
- Extend the public target
Degree of development:
Patents/Rights: Others
Requested Cooperation: License Agreement, Quality control, Maintenance, Joint Venture Agreement
- Type of partner sought:
Partners to distribute the device
- Specific area of activity of the partner:
Diagnostic devices in cardiology and vascular; medical devices distribution
- Task to be performed by the partner sought:
Marketing, sales and first level support
Type of Organisation:
Status: NEW
| 
